<table id="table19" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 19: The Effect of Concomitant Medications that Affect the Gastric pH and Gastric Motility on the Pharmacokinetics of Posaconazole Oral Suspension in Healthy Volunteers</caption>
<col align="left" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="center" valign="top" width="20%"></col>
<thead>
<tr stylecode="Botrule">
<th align="center" rowspan="2" stylecode="Lrule Rrule" valign="bottom">Coadministered Drug (Postulated Mechanism of Interaction)</th>
<th rowspan="2" stylecode="Rrule" valign="bottom">Coadministered Drug Dose/Schedule</th>
<th align="center" rowspan="2" stylecode="Rrule" valign="bottom">Posaconazole Dose/Schedule</th>
<th colspan="2" stylecode="Rrule" valign="bottom">Effect on Bioavailability of Posaconazole</th>
</tr>
<tr stylecode="Botrule">
<th align="center" stylecode="Rrule">Change in Mean<br/>C<sub>max</sub>
<br/>(ratio estimate<footnote id="t14f1">Ratio Estimate is the ratio of coadministered drug plus posaconazole to coadministered drug alone for C<sub>max</sub> or AUC.</footnote>; 90% CI of the ratio estimate)</th>
<th stylecode="Rrule">Change in Mean AUC<br/>(ratio estimate<footnoteref idref="t14f1"></footnoteref>; 90% CI of the ratio estimate)</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Cimetidine<br/>(Alteration of gastric pH)</td>
<td stylecode="Rrule">400 mg BID × 10 days</td>
<td stylecode="Rrule">200 mg (tablets) QD × 10 days<footnote>The tablet refers to a non-commercial tablet formulation without polymer.</footnote>
</td>
<td stylecode="Rrule">↓ 39%<br/>(0.61; 0.53-0.70)</td>
<td stylecode="Rrule">↓ 39%<br/>(0.61; 0.54-0.69)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Esomeprazole (Increase in gastric pH)<footnote id="t14f2">The drug interactions associated with the oral suspension are also relevant for the delayed-release tablet with the exception of Esomeprazole and Metoclopramide.</footnote>
</td>
<td stylecode="Rrule" valign="middle">40 mg QAM × 3 days</td>
<td stylecode="Rrule">400 mg (oral suspension) single dose</td>
<td stylecode="Rrule" valign="middle">↓ 46%<br/>(0.54; 0.43-0.69)</td>
<td stylecode="Rrule" valign="middle">↓ 32%<br/>(0.68; 0.57-0.81)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Metoclopramide (Increase in gastric motility)<footnoteref idref="t14f2"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">10 mg TID × 2 days</td>
<td stylecode="Rrule">400 mg (oral suspension) single dose</td>
<td stylecode="Rrule" valign="middle">↓ 21%<br/>(0.79; 0.72-0.87)</td>
<td stylecode="Rrule" valign="middle">↓ 19%<br/>(0.81; 0.72-0.91)</td>
</tr>
</tbody>
</table>